Next Article in Journal
Dental Undergraduate Views of Objective Structured Clinical Examinations (OSCEs): A Literature Review
Next Article in Special Issue
Direct Oral Anticoagulants in Dental Patients Including the Frail Elderly Population
Previous Article in Journal
Infection and Pulp Regeneration
Previous Article in Special Issue
A Study of the Management of Patients Taking Novel Oral Antiplatelet or Direct Oral Anticoagulant Medication Undergoing Dental Surgery in a Rural Setting
Article Menu

Export Article

Open AccessReview
Dent. J. 2016, 4(1), 5;

New Direct Oral Anticoagulants (DOAC) and Their Use Today

Heike Schwarb, Diagnostic Hematology, University Hospital Basel, CH-4031 Basel, Switzerland
Author to whom correspondence should be addressed.
Academic Editor: Claude Jaquiéry
Received: 10 January 2016 / Revised: 5 March 2016 / Accepted: 9 March 2016 / Published: 11 March 2016
(This article belongs to the Special Issue Medically Compromised Patients in Dentistry)
Full-Text   |   PDF [465 KB, uploaded 11 March 2016]   |  


The ideal anticoagulant is oral, has a wide therapeutic range, predictable pharmacokinetics and pharmacodynamics, a rapid onset of action, an available antidote, minimal side effects and minimal interactions with other drugs or food. With the development of the novel direct oral anticoagulants (DOAC), we now have an alternative to the traditional vitamin K antagonists (VKA) for the prevention and treatment of thrombosis. DOACs have limited monitoring requirements and very predictable pharmacokinetic profiles. They were shown to be non-inferior or superior to VKA in the prophylaxis or treatment of thromboembolic events. Particularly in terms of safety they were associated with less major bleeding, including intracranial bleeding, thus providing a superior benefit for the prevention of stroke in patients with atrial fibrillation. Despite these advantages, there are remaining limitations with DOACs: their dependence on renal and hepatic function for clearance and the lack of an approved reversal agent, whereas such antidotes are successively being made available. DOACs do not need regular monitoring to assess the treatment effect but, on the other hand, they interact with other drugs and interfere with functional coagulation assays. From a practical point of view, the properties of oral administration, simple dosing without monitoring, a short half-life allowing for the possibility of uncomplicated switching or bridging, and proven safety overwhelm the disadvantages, making them an attractive option for short- or long-term anticoagulation. View Full-Text
Keywords: oral anticoagulants; non-VKA oral anticoagulants (NOAC); DOAC; rivaroxaban; apixaban; edoxaban; dabigatran oral anticoagulants; non-VKA oral anticoagulants (NOAC); DOAC; rivaroxaban; apixaban; edoxaban; dabigatran

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Schwarb, H.; Tsakiris, D.A. New Direct Oral Anticoagulants (DOAC) and Their Use Today. Dent. J. 2016, 4, 5.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Dent. J. EISSN 2304-6767 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top